Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis to Present at Jefferies 2017 Global Healthcare Conference

Business Wire June 7, 2017

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire June 5, 2017

Biotech Stock Performance Review -- 22nd Century, Calithera Biosciences, Five Prime Therapeutics, and Advaxis

PR Newswire June 5, 2017

Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials

PR Newswire June 1, 2017

Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer

Business Wire May 30, 2017

Advaxis to Host Investor & Analyst Day on June 12

Business Wire May 18, 2017

Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

Business Wire May 15, 2017

Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis

Business Wire May 5, 2017

Advaxis Recognized as One of New Jersey’s “Best Places to Work 2017”

Business Wire April 27, 2017

Research Reports Initiation on Biotech Stocks -- La Jolla Pharma, Spectrum Pharma, Advaxis, and Aevi Genomic

PR Newswire April 10, 2017

Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

GlobeNewswire March 27, 2017

EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer

GlobeNewswire March 23, 2017

Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer

GlobeNewswire March 15, 2017

Advaxis to Present at the 2017 Barclays Global Healthcare Conference

GlobeNewswire March 13, 2017

Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical

GlobeNewswire March 7, 2017

How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

PR Newswire March 7, 2017

20 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  March 6, 2017

Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO

GlobeNewswire March 6, 2017

Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

GlobeNewswire March 2, 2017

Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

GlobeNewswire February 27, 2017